Fact-checked by Grok 2 weeks ago

Intrathecal administration

Intrathecal administration is a method that involves injecting medications directly into the subarachnoid space—the region surrounding the containing (CSF)—to achieve precise effects on the (CNS). This approach circumvents the blood-brain barrier, permitting the use of much smaller doses (often 1/300th of oral equivalents for opioids like ) while minimizing systemic exposure and side effects. The practice traces its origins to the late , when German surgeon pioneered intrathecal injection of for spinal anesthesia in 1898, marking the first successful use of this route for localized pain relief during surgery. By the mid-20th century, advancements in understanding CSF dynamics and expanded its applications beyond acute anesthesia; the first implantable intrathecal pump for continuous infusion was introduced in 1981 to manage intractable . Today, it encompasses both temporary bolus injections via and long-term systems using programmable pumps implanted in the , connected to thin catheters threaded into the intrathecal space (typically at levels L2-S1 under fluoroscopic guidance). Intrathecal administration is indicated primarily for refractory , including non-malignant conditions like failed back surgery syndrome and , as well as cancer-related pain where oral opioids fail or cause intolerable side effects. It is also a cornerstone for managing severe in disorders such as , , and , using agents like . Emerging uses include antimicrobial therapy for CNS infections caused by resistant pathogens (e.g., cryptococcal meningitis). Experimental treatments for neurodegenerative diseases like Alzheimer's are also under investigation, where direct CSF access enhances drug penetration into brain tissue. FDA-approved intrathecal formulations are limited but include sulfate, (a non-opioid analgesic), and , often combined in customized solutions for optimal efficacy. The benefits of intrathecal administration include superior analgesia and control with fewer gastrointestinal, respiratory, and cognitive adverse effects compared to systemic routes, leading to improved and reduced healthcare costs over time. However, it carries risks such as (occurring in about 2-5% of cases), catheter migration or occlusion, cerebrospinal fluid leaks, and the formation of inflammatory granulomas from high-concentration opioids, necessitating careful selection, trialing, and monitoring. Ongoing research into , such as liposomal-encapsulated drugs, aims to further refine , sustain , and mitigate these complications.

Definition and principles

Definition

Intrathecal administration refers to the injection or of drugs directly into the subarachnoid space surrounding the , where they access the (CSF) to enable targeted delivery to the (CNS). This route involves delivering substances into the containing CSF, typically via or implanted devices, allowing drugs to bypass the blood-brain barrier that restricts many systemic therapies from reaching the and effectively. The primary purposes of intrathecal administration include achieving high local concentrations of therapeutic agents within the CNS while using substantially lower doses than required for systemic routes, thereby minimizing off-target effects and reducing systemic toxicity. It is commonly employed for , (such as in chronic non-cancer or cancer-related ), for leptomeningeal metastases, and other CNS-targeted therapies like treatment with . Drugs intended for intrathecal use must be sterile, pyrogen-free, and preservative-free formulations to avoid risks associated with preservatives such as , which can cause severe toxicity when introduced into the .

Intrathecal administration delivers drugs directly into the subarachnoid space, where they mix with () to bypass the . This direct access circumvents the need for systemic circulation, allowing therapeutic agents to reach targets that are otherwise impermeable. Once in the , drugs exert their effects by diffusing across the and arachnoid membranes into the spinal cord and dorsal horn receptors, while also distributing to the and higher brain regions via bulk flow along pathways, passive diffusion driven by concentration gradients, and perivascular transport through basement membranes surrounding vessels of varying calibers. The of intrathecally administered drugs feature a rapid onset, often within 3-5 minutes for local anesthetics due to immediate high concentrations at neural sites, and 5-20 minutes for lipophilic opioids. The CSF serves as a , contributing to prolonged duration of action by maintaining elevated local levels even as concentrations decline, with effects lasting hours to days depending on the agent. Clearance primarily occurs through bulk absorption into via arachnoid granulations in the cranium and spinal nerve root sheaths, supplemented by spinal perineural uptake, resulting in a in CSF that can extend beyond initial distribution phases. Post-injection, drug concentrations form a highest in the lumbar CSF, facilitating rostral spread through CSF circulation at rates of approximately 1-2 cm/min in , enabling cephalad progression to cisternal levels within 30-60 minutes. This initial lumbar dominance shifts as the drug disperses, with roughly half of the total adult CSF volume (150 mL) residing in the spinal subarachnoid to influence dilution and flow. Factors such as drug lipophilicity modulate distribution—hydrophilic agents like exhibit greater rostral and circumferential spread due to slower tissue uptake, whereas lipophilic ones like localize more segmentally with limited ascent. positioning (e.g., sitting versus lateral) alters baricity and gravitational flow, further affecting spread extent, alongside variations in total CSF volume (150-200 mL in ).

Anatomy and physiology

Spinal anatomy

The subarachnoid space is the meningeal compartment located between the and the , surrounding the and nerve roots while containing (CSF). This space extends continuously from the at the to the second sacral vertebra (), providing a conduit for CSF that cushions and supports the . Within the spinal region, the subarachnoid space is bridged by delicate arachnoid trabeculae, which span the gap between the arachnoid and pia layers, and it houses major blood vessels supplying the . Key structures delineating the subarachnoid space include the dura mater, which forms the outermost meningeal barrier and encloses the space inferior to the skull base. External to the dura lies the epidural space, a potential compartment filled with adipose tissue and venous plexuses between the dura and the vertebral canal walls. In the lower spinal region, the subarachnoid space encompasses the cauda equina, a bundle of lumbosacral nerve roots that descend from the conus medullaris of the spinal cord. The lumbar cistern represents an enlarged portion of the subarachnoid space, extending from the (typically ending at the L1-L2 vertebral level in adults) to the termination of the dural sac at S2. This cistern contains CSF and the nerve roots, making the L3-L4 intervertebral space an ideal access point for intrathecal procedures, as it avoids direct contact with the . Anatomical variations can influence access to the subarachnoid space, such as tethered cord syndrome, where inelastic tissue anchors the below its normal L1-L2 position, potentially increasing the risk of neural injury during procedures. Similarly, , characterized by narrowing of the due to degenerative changes, may compress the subarachnoid space and complicate needle insertion by limiting patency.

Cerebrospinal fluid dynamics

(CSF) is primarily produced by the , a specialized ependymal located within the lateral, third, and fourth ventricles of the . The actively secretes CSF at a rate of approximately 20 mL per hour, resulting in a total daily production of about 500 mL in adults. This production maintains a , with the entire CSF volume turning over approximately 4 to 5 times per day, equivalent to a renewal every 5 to 6 hours. Once produced, CSF circulates through a defined pathway beginning in the . It flows from the via the foramina of Monro into the third ventricle, then passes through the to the . From there, it exits into the subarachnoid space through the lateral foramina of Luschka and the median foramen of Magendie. In the subarachnoid space—the circulation pathway surrounding the and —CSF generally moves downward along the spinal cord before ascending over the cerebral convexities, where it is primarily absorbed via the arachnoid villi (or granulations) into the . The subarachnoid space thus serves as the key conduit for this bulk flow, influenced by factors such as cardiac pulsations and . The total volume of CSF in an adult is approximately 150 mL, with roughly 25 to 30 mL residing within the intracranial ventricles and the majority distributed in the subarachnoid spaces surrounding the and . Normal CSF pressure, typically measured via in the lateral decubitus position, ranges from 6 to 25 cm H₂O. Physiological factors, including body posture, can modulate CSF flow dynamics; for instance, the upright sitting position promotes greater caudal distribution along the spinal axis due to gravitational influences on fluid movement. CSF plays essential roles in central nervous system homeostasis, acting as a mechanical buffer to cushion the and against from daily movements and impacts. It also facilitates the transport of nutrients, hormones, and signaling molecules to neural tissues while enabling the clearance of metabolic waste products, thereby maintaining an optimal microenvironment for neuronal function. Chemically, CSF is characterized by a of about 7.3 and a specific of 1.006 to 1.009, properties that contribute to its buoyant support of neural structures.

Administration techniques

Single-dose injection

Single-dose intrathecal injection involves the one-time administration of a directly into the subarachnoid space via , primarily for acute applications such as or short-term analgesia. This technique allows for rapid onset of effect due to the direct exposure of the drug to , with effects typically lasting 1-4 hours depending on the agent used. The procedure begins with careful patient positioning to optimize access to the lumbar spine, either in the lateral decubitus position with the neck and knees flexed or in the sitting position with forward flexion and support. Aseptic technique is essential, involving the use of sterile gloves, gown, mask, and hat; the skin at the insertion site is prepared with or iodine solution and draped sterilely. Local anesthetic, such as 1-2% lidocaine, is infiltrated subcutaneously using a 25-gauge needle to minimize discomfort. The injection site is selected at the L3-L5 intervertebral spaces, identified using anatomical landmarks like the iliac crests to ensure placement below the termination. A 22-25 spinal needle, such as a Quincke (cutting ) or Sprotte (pencil-point) type, is used for insertion, with the oriented to the dural fibers to reduce . The needle is advanced at a 10-15 degree cephalad angle toward the umbilicus in incremental steps of 2-3 mm, periodically removing the stylet to check for (CSF) flow, which confirms entry into the subarachnoid space. In cases of or anatomical challenges, guidance may be employed to identify the interspace and depth, improving accuracy and safety. Once confirmed, the medication is injected slowly (e.g., at less than 0.5 mL per second) in a total volume limited to 2-5 mL to prevent excessive rise; an equivalent volume of CSF may be withdrawn beforehand if needed. Following injection, the needle is withdrawn, and the patient is monitored for immediate complications such as , respiratory , or CSF leakage, with checked frequently. Post-procedure, the patient remains or prone for at least 1 hour to aid drug distribution and reduce risk, while is encouraged. This method is indicated for procedures requiring temporary spinal blockade, providing reliable analgesia or with a low volume of agent due to the direct CSF contact.

Continuous infusion systems

Continuous infusion systems for intrathecal administration enable sustained directly into the , providing stable therapeutic levels for chronic conditions such as or . These systems typically involve placement connected to either external or implantable pumps, allowing for fixed or programmable rates over extended periods. Catheter-based temporary systems utilize or tunneled s inserted via to deliver drugs at fixed rates through external pumps for durations ranging from days to weeks. These setups are commonly employed for therapeutic trials to assess response prior to permanent implantation, facilitating dose in a controlled setting. Implanted systems consist of programmable intrathecal pumps, such as the SynchroMed III (as of 2023, featuring upgradable and enhanced durability), which feature reservoirs of 20-40 mL capacity and are surgically placed subcutaneously in the under fluoroscopic guidance. These devices support continuous, bolus, or patient-activated infusions and require refills every 1-6 months depending on dosage and reservoir size, lasting up to 7 years at typical flow rates. Techniques for catheter placement involve advancing the tip to targeted spinal levels, such as T10-L1 for lower body to optimize drug distribution via dynamics, or cervical levels for broader upper body effects. Patient selection emphasizes those with symptoms unresponsive to conservative therapies, beginning with a temporary trial to confirm before proceeding to implantation. Maintenance includes non-invasive reprogramming via to adjust parameters, along with annual evaluations using to detect potential occlusion or migration, ensuring long-term system integrity.

Clinical applications

and

Intrathecal administration plays a key role in perioperative , particularly for procedures requiring rapid and reliable sensory and motor blockade, such as cesarean sections and lower abdominal surgeries. Local anesthetics like bupivacaine and are commonly used for single-shot spinal blocks, with typical doses of 10-15 mg for bupivacaine and 15-20 mg for to achieve adequate up to the T4 dermatome level. These agents provide profound blockade lasting 2-4 hours, often combined with opioids such as (10-25 mcg) or (0.1-0.5 mg) to enhance analgesia and extend postoperative pain relief without significantly prolonging motor recovery. For example, in cesarean sections, a single-shot protocol involving 10-12 mg bupivacaine with 10-20 mcg or 0.1-0.2 mg offers effective intraoperative and reduces the need for supplemental systemic opioids in the immediate postoperative period. In chronic management, particularly for cancer-related cases, continuous intrathecal infusions deliver targeted analgesia directly to the , minimizing systemic side effects. such as are initiated at 0.1-1.0 mg per day and titrated based on response, often equating to 10-20% of the prior oral equivalent dose to achieve optimal control. Adjunctive agents include alpha-2 agonists like (30-75 mcg initial dose) or (3-10 mcg), which potentiate effects and improve analgesia duration when added to infusions. , a non- of N-type calcium channels, is used for severe at starting doses of 0.5-1.2 mcg/day, titrated up to 21 mcg/day, providing analgesia independent of receptors. Combined infusions, such as with bupivacaine (1-14 mg/day), enhance efficacy in refractory by providing both local and central analgesia, often resulting in 50-70% reduction in patients unresponsive to systemic . Clinical trials demonstrate that intrathecal yields moderate to complete relief in over 50% of cases, with functional improvements and reduced oral requirements. A 2025 study on postoperative introduced intrathecal (250-300 mcg) combined with (25 mg), which increased opioid avoidance rates to 57% compared to 14% in historical controls, thereby reducing overall needs through enhanced analgesia.

Infectious disease therapy

Intrathecal administration of antimicrobial agents is employed as an adjunctive therapy for (CNS) infections where systemic antibiotics achieve inadequate (CSF) concentrations, particularly in cases of bacterial , fungal , and select resistant infections. This route bypasses the blood-brain barrier to deliver high local drug levels directly into the CSF, targeting pathogens such as multidrug-resistant or fungi that poorly penetrate the CNS. For , intrathecal is indicated in cryptococcal or coccidioidal cases refractory to , with typical dosages ranging from 0.1 to 1 mg per day administered via or intraventricular reservoir. In bacterial , particularly post-neurosurgical infections caused by Gram-negative organisms, intrathecal gentamicin is used at doses of 4-8 mg daily, often combined with intravenous antibiotics to achieve rapid CSF sterilization. CNS infections have limited indications for intrathecal therapy; trials with intrathecal acyclovir have been explored for meningitis but remain investigational and not standard due to sufficient intravenous efficacy in most cases. Protocols typically involve daily intrathecal injections through or ventricular access as an adjunct to systemic antimicrobials, continuing for 2-4 weeks or until CSF cultures are negative and clinical improvement is evident, with dosing adjusted based on CSF drug levels targeting 10-20 times the pathogen's . Efficacy is supported by studies showing improved microbiological clearance and reduced mortality in resistant cases; for instance, intrathecal amphotericin B enhances outcomes in amphotericin-resistant by achieving sustained CSF fungicidal activity. Historically, intrathecal was a cornerstone in treatment during the mid-20th century, prolonging survival in otherwise fatal cases before modern rifampin-based regimens supplanted it. Challenges include the poor CSF penetration of most antibiotics (often <10% of serum levels), necessitating intrathecal routes for agents like polymyxins or vancomycin in multidrug-resistant infections such as those caused by carbapenem-resistant Acinetobacter baumannii, where intravenous therapy alone fails to eradicate pathogens. Intraventricular polymyxin B, dosed at 1-2 mg daily, has demonstrated higher clinical cure rates (up to 80%) in such scenarios when combined with systemic drugs, though risks of chemical ventriculitis require careful monitoring.

Cancer treatment

Intrathecal administration plays a critical role in treating central nervous system (CNS) malignancies and leptomeningeal disease, where systemic chemotherapy often fails to achieve therapeutic concentrations due to the blood-brain barrier. Primary indications include with CNS involvement, non-Hodgkin lymphoma affecting the meninges, and leptomeningeal metastases from solid tumors such as . In ALL, intrathecal therapy is used both prophylactically and therapeutically to prevent or treat CNS relapse, which occurs in up to 5-10% of cases without intervention. For , it targets leptomeningeal spread, particularly in high-risk diffuse large B-cell subtypes. leptomeningeal metastases, often presenting with cytologic positivity in cerebrospinal fluid, benefit from intrathecal approaches to improve survival and neurologic function. Common chemotherapeutic agents administered intrathecally include methotrexate, cytarabine, and thiotepa, often combined with hydrocortisone to mitigate arachnoiditis and inflammation. Methotrexate is typically dosed at 12 mg for adults via lumbar puncture or 6 mg via Ommaya reservoir, providing effective CNS penetration for leukemia prophylaxis and treatment. Cytarabine, in its standard form, is given at 30-50 mg, while the liposomal formulation (DepoCyt) allows sustained release at a 50 mg dose every two weeks, extending the half-life in cerebrospinal fluid to over 100 hours compared to hours for free cytarabine. Thiotepa is administered at 10 mg per dose for lymphoma-related leptomeningeal disease, offering alkylating activity with good CSF distribution. Triple intrathecal therapy—combining methotrexate (12 mg), cytarabine (30 mg), and hydrocortisone (15 mg)—is frequently used in ALL to enhance efficacy while reducing chemical meningitis risk. Treatment protocols generally involve an induction phase of weekly injections for 4-8 weeks, followed by consolidation and maintenance dosing every 1-4 weeks, tailored to disease response and cytologic clearance in cerebrospinal fluid. For recurrent or refractory cases, intraventricular access via an Ommaya reservoir—a subcutaneous device implanted in the frontal scalp connected to the lateral ventricle—facilitates repeated administration and improves drug distribution throughout the neuraxis. This approach is particularly valuable in lymphoma and solid tumor metastases, where lumbar injections may yield uneven CSF exposure. Overall, these regimens can achieve cytologic remission rates of 20-60% in leptomeningeal disease, though survival benefits vary by primary tumor histology. A critical safety consideration is the prohibition of intrathecal vincristine, as inadvertent administration causes fatal ascending paralysis and myeloencephalopathy due to its neurotoxicity in cerebrospinal fluid. Protocols mandate distinct syringe labeling and verification to prevent such errors. As of 2025, advancements in nanoparticle-enhanced intrathecal delivery are emerging to improve tumor targeting and reduce systemic toxicity, such as degradable polymer nanoparticles loaded with PARP inhibitors that achieve prolonged retention in leptomeningeal metastases. These carriers enhance drug stability and penetration into meningeal lesions, showing promise in preclinical models for ALL and breast cancer CNS involvement.

Neurological disorder management

Intrathecal administration plays a crucial role in managing neurological disorders by delivering neuromodulators directly to the central nervous system, bypassing systemic barriers to achieve targeted therapeutic effects with reduced side effects compared to oral routes. This approach is particularly valuable for conditions involving spasticity, genetic neuromuscular deficits, and specific neurodegenerative processes, where approved agents like and have demonstrated clinical benefits. In spasticity management, intrathecal baclofen is a standard therapy for patients with cerebral palsy or multiple sclerosis whose symptoms are refractory to oral medications. Baclofen, a GABA-B receptor agonist, reduces muscle tone by inhibiting monosynaptic and polysynaptic reflexes at the spinal level. Typical dosing ranges from 50 to 1000 mcg per day via an implanted pump, titrated based on individual response to optimize symptom control while minimizing adverse effects. For genetic disorders, intrathecal ASOs such as nusinersen address underlying molecular defects in spinal muscular atrophy (SMA). Nusinersen, administered at 12 mg every 4 months following initial loading doses, modulates splicing of the SMN2 gene to increase functional SMN protein production, thereby supporting motor neuron survival and function. In infants with SMA type 1, treatment has led to significant motor function gains, with improvements in milestones like sitting and standing observed in clinical trials. Similarly, tofersen targets superoxide dismutase 1 (SOD1)-associated amyotrophic lateral sclerosis (ALS), a neurodegenerative condition, by reducing toxic SOD1 protein levels. Approved by the FDA in 2023 under accelerated approval, it is dosed at 100 mg every 4 weeks intrathecally and has shown reductions in cerebrospinal fluid SOD1 protein by approximately 35% within eight weeks, alongside decreases in neurofilament light chain as a biomarker of neuronal damage. Treatment protocols often begin with a screening trial using a 50 mcg intrathecal test dose of to assess responsiveness, typically via bolus injection under fluoroscopic guidance; a positive response, defined as at least a two-grade reduction on the , proceeds to pump implantation for continuous infusion. For severe cases, such as advanced spasticity or progressive genetic conditions, lifelong intrathecal infusion may be required, with periodic dose adjustments and pump refills every 1-3 months. Efficacy data indicate substantial spasticity reduction with intrathecal , often achieving 70-80% improvement in muscle tone scores in responsive patients, enhancing mobility and quality of life. In SMA infants, yields motor gains, with up to 41% showing clinically meaningful improvements in function over 13 months.

Emerging therapies

Recent advancements in intrathecal administration have focused on regenerative and gene-based therapies for neurological conditions, particularly those involving spinal cord injury and neurodegenerative diseases. Stem cell therapies, such as intrathecal delivery of mesenchymal stem cells (MSCs) derived from bone marrow or adipose tissue, have shown promise in treating traumatic spinal cord injury (SCI). In a phase I clinical trial involving autologous adipose-derived MSCs, 70% of participants exhibited improvements in American Spinal Injury Association (ASIA) impairment grades, with notable gains in motor and sensory function levels by week 96 post-injection. A 2025 meta-analysis further confirmed that intrathecal MSCs significantly enhance motor scores and activities of daily living in SCI patients, with preclinical and early clinical data indicating functional recovery through neuroprotection and tissue repair mechanisms. Antisense oligonucleotides (ASOs) are expanding beyond established uses in spinal muscular atrophy and amyotrophic lateral sclerosis to target other genetic disorders via intrathecal routes. For Huntington's disease, the investigational ASO tominersen, administered intrathecally every 16 weeks, is under evaluation in the ongoing phase 2 GENERATION HD2 trial, which has enrolled 301 early-stage patients and reported no major safety issues as of 2025, with dosing optimized to 100 mg for potential clinical benefit in reducing mutant huntingtin protein. Novel carriers like extracellular vesicles (EVs) and nanoparticles are being explored for enhanced neuroprotection and targeted delivery. Intrathecal injection of EVs, including those derived from red blood cells, has demonstrated neuroprotective effects in spinal cord trauma models by mediating anti-inflammatory responses and promoting axonal regeneration, as evidenced in 2025 preclinical studies leveraging EVs as drug vehicles. For Parkinson's disease, intrathecal nanoparticles facilitate targeted crossing of the blood-cerebrospinal fluid barrier, improving distribution of therapeutics like gene vectors to address dopaminergic neuron loss, with phase 1/2 trials showing dose-dependent reductions in pathological proteins. Intracisternal delivery, a variant of intrathecal administration targeting high-cervical regions, is gaining traction for refractory pain management, offering precise localization for upper spinal analgesia. The broader intrathecal therapy market, including such applications, is projected to reach $2.45 billion globally by 2025, driven by a 5% compound annual growth rate amid rising demand for advanced pain interventions. Many of these emerging therapies are in phase II/III trials, emphasizing safety profiles and efficacy endpoints like functional recovery, though ethical concerns around off-label use persist, including informed consent for experimental risks and equitable access in non-approved settings.

Risks and complications

Procedural risks

Intrathecal administration, particularly via implanted pumps and catheters, carries procedural risks primarily related to surgical implantation and device maintenance. Implantation complications include infections, which occur in 1-5% of cases and may manifest as pocket erosion or wound dehiscence, often requiring device explantation and antibiotic therapy. Bleeding or hematoma formation at the implantation site is rare, occurring in less than 1% of implantation procedures, potentially leading to pain, swelling, or compression if not addressed promptly. Cerebrospinal fluid (CSF) leaks are more common, reported in 10-30% of procedures, frequently causing post-dural puncture headaches due to intracranial hypotension. Catheter-related issues further contribute to procedural risks. Migration of the catheter tip occurs in approximately 6% of cases, potentially disrupting drug delivery and necessitating repositioning under fluoroscopy. Occlusion or granuloma formation—inflammatory masses at the catheter tip—affects 0.1-3% of patients, leading to reduced efficacy or neurological symptoms that may require surgical revision. Spinal cord injury from catheter placement or migration is rare, with an incidence below 0.1%. Device failures pose additional challenges in long-term use. Pump motor stalls, which interrupt infusion and can cause withdrawal symptoms, occur in roughly 12% of reported adverse events. Battery depletion is an expected endpoint, typically after 5-7 years, while annual revision rates due to various mechanical issues range from 5-10%. Recent advancements, such as absorbable antibacterial envelopes, have been shown to reduce surgical site infections in (as of 2025). To mitigate these risks, strategies include preoperative antibiotic prophylaxis to reduce infection rates, intraoperative fluoroscopy for precise catheter placement, and thorough patient screening for coagulopathy to minimize bleeding complications. These measures, combined with careful surgical techniques such as dural sealing to prevent CSF leaks, enhance safety during implantation.

Pharmacological effects

Intrathecal administration of opioids can lead to several adverse pharmacological effects due to their direct action on spinal opioid receptors. Respiratory depression, characterized by hypoventilation rates below 10 breaths per minute, is a serious dose-dependent risk, particularly with hydrophilic agents like morphine, occurring in up to 1-2% of perioperative cases. Pruritus affects 30-80% of patients, often generalized and mediated by central mu-opioid receptor activation, while nausea and vomiting occur in approximately 20%, linked to chemoreceptor trigger zone stimulation. Urinary retention is common, resulting from opioid-induced detrusor muscle relaxation and sphincter contraction, with incidences ranging from 20-50% in postoperative settings. Local anesthetics delivered intrathecally primarily cause hemodynamic instability through sympathetic blockade, leading to hypotension in 10-30% of cases and reflex bradycardia, especially in obstetric or lower thoracic applications. Prolonged or repeated exposure increases the risk of neurotoxicity, manifesting as , which involves persistent sacral sensory deficits, bowel/bladder dysfunction, and lower limb weakness; this has been associated with continuous spinal techniques using hyperbaric solutions, with an estimated incidence of about 1 in 200 cases. Among other agents, ziconotide, a selective N-type calcium channel blocker, commonly induces central nervous system effects including dizziness (up to 46%), nystagmus (uncontrolled eye movements in 5-10%), and confusion, with rare but severe risks of suicidal ideation highlighted in product warnings. Intrathecal baclofen withdrawal, often due to pump failure or abrupt discontinuation, can precipitate life-threatening symptoms such as seizures, hyperthermia exceeding 40°C, rebound spasticity, and altered mental status, mimicking sepsis in severe instances. Chemotherapeutic agents like or cytarabine administered intrathecally may cause chemical arachnoiditis, presenting as aseptic meningitis with headache and radicular pain in 10-20% of administrations, alongside myelosuppression leading to pancytopenia through direct spinal cord toxicity. Management of these effects emphasizes careful dose titration to minimize receptor overstimulation, with opioid-related adverse events often responsive to low-dose intravenous naloxone infusions (e.g., 0.25-1 mcg/kg/hour) that reverse respiratory depression and pruritus without precipitating withdrawal. Incidence of complications like catheter-tip granulomas, inflammatory masses causing spinal cord compression, is notably higher with high-concentration morphine mixtures (e.g., >20 mg/mL), necessitating concentration limits below 15 mg/mL in guidelines.

Historical development

Early discoveries

The origins of intrathecal administration trace back to the late 19th century, when neurologists began exploring the spinal cord as a target for local anesthetics to achieve targeted analgesia. In 1885, James Leonard Corning, a New York neurologist, conducted the first documented experiments with intrathecal cocaine injection. Initially testing on a dog by injecting approximately 1.3 ml of a 2% cocaine solution between the inferior dorsal vertebrae, Corning observed rapid onset of hindquarter anesthesia and motor incoordination within five minutes, with effects resolving after about four hours. He then applied the technique to a human patient suffering from spinal weakness and seminal incontinence—a condition involving chronic pain and neurological dysfunction—administering around 2 ml of a 3% cocaine solution at the T11-T12 interspace, which produced sensory loss in the legs, genitalia, and lumbar region without significant motor impairment, though followed by headache and vertigo. These experiments, aimed at simulating myelitis-like anesthesia for pain relief in neurological and potentially gynecological contexts, were published as "Spinal anaesthesia and local medication of the cord," marking the inadvertent inception of spinal block techniques. August Bier advanced intrathecal administration toward clinical in 1898 in . On August 16, Bier performed the first successful surgical operation under intrathecal on a patient undergoing resection of a tuberculous ankle joint at the University of Kiel, achieving effective analgesia without general . Later, on August 24, Bier and his assistant Hildebrandt conducted self-experiments by puncturing each other's subarachnoid spaces with solutions (up to 15 mg), confirming profound lower-body , loss of sensation, and temporary , with recovery aided by stimulants like ; Bier reported personal experiences of leg numbness and even tested reflexes by striking his shin with a hammer. These experiments, undertaken to investigate post-procedure headaches, demonstrated the feasibility and relative safety of the method for operative use, though early complications such as headaches, , and occasional were noted, paving the way for broader adoption despite ongoing debates. Bier's findings, published in 1899, established intrathecal as a viable alternative to inhalation. The introduction of opioids into intrathecal administration occurred shortly thereafter, expanding its scope beyond local anesthetics for postoperative . In 1901, surgeon Nicolae Racoviceanu-Pitesti reported the first use of intrathecal in , injecting the alongside to provide prolonged spinal analgesia following . This combination aimed to enhance and extend relief in the postoperative period, leveraging morphine's affinity for spinal opioid receptors to suppress nociceptive transmission without systemic overdose risks. Pitesti's work highlighted the potential for selective analgesia but was met with caution due to limited follow-up data. By the 1930s, intrathecal administration saw limited clinical use amid growing concerns over toxicity and complications from early agents like , including severe headaches, infections, , and rare fatalities from or total spinal block. These fears, documented in reports of high morbidity rates, led to a decline in enthusiasm following the initial post-Bier surge, with practitioners favoring epidural routes or general for safety. Interest revived in the mid-1930s through exploring alternative agents, encouraging cautious re-evaluation of intrathecal techniques with improved antiseptics and hyperbaric solutions.

Modern advancements

The of pain, proposed by Ronald Melzack and Patrick Wall in 1965, provided a foundational framework for understanding spinal modulation of pain signals and spurred subsequent research into targeted intrathecal opioid delivery in the 1970s and 1980s, leading to clinical trials that demonstrated reduced systemic side effects compared to . In , the first intrathecal administration of was reported for treating of spinal origin, marking a pivotal advancement in by enabling direct delivery to achieve higher local concentrations with lower doses. The 1990s saw significant technological progress with the U.S. (FDA) approval in 1991 of the first programmable, implantable intrathecal systems (IDDS), such as the SynchroMed pump, which allowed precise, adjustable dosing for and management. Concurrently, clinical trials for , a synthetic derived from venom, began in the mid-1990s, evaluating its intrathecal use for refractory through randomized, placebo-controlled studies that highlighted its efficacy in non-opioid analgesia. In the 2000s and , standardization of intrathecal advanced with the FDA approval of liposomal cytarabine (DepoCyt), a sustained-release formulation that extended drug residence time in , improving outcomes in lymphomatous meningitis by reducing injection frequency from daily to biweekly. A landmark regulatory milestone occurred in 2016 with FDA approval of (Spinraza), the first antisense oligonucleotide therapy for (), administered intrathecally to modulate SMN2 splicing and achieve motor function improvements in pediatric and adult patients across SMA types. The 2020s have introduced gene-targeted and nanotechnology-driven innovations, exemplified by the 2023 FDA accelerated approval of (Qalsody) for (ALS) associated with SOD1 mutations, an intrathecal antisense that reduces light chain levels as a surrogate for neurodegeneration. Emerging research in 2024–2025 has focused on extracellular vesicles (EVs) and nanoparticles for enhanced intrathecal delivery, including clinical trials of EV-based therapies like NouvSoma001 for , which leverage EVs' biocompatibility for nucleic acid transport across the blood-cerebrospinal fluid barrier. Similarly, lipid nanoparticle formulations have shown promise in preclinical studies for mRNA delivery to tissues via intrathecal injection, achieving efficient neuronal expression with minimal . In 2025, studies on high-cervical intrathecal drug delivery have demonstrated efficacy for refractory neuropathic craniofacial pain, with trials reporting over 50% pain reduction in select patients using targeted and local anesthetic combinations without significant adverse effects.

References

  1. [1]
    Intrathecal Drug Delivery in the Era of Nanomedicine - PMC
    Intrathecal (IT) administration, i.e., the injection of substances directly into the thecal sac that contains cerebrospinal fluid (CSF), is a potentially ...
  2. [2]
    Implantable Intrathecal Drug Delivery System - StatPearls - NCBI - NIH
    Jul 19, 2024 · Implantable intrathecal drug delivery systems are typically employed in patients with chronic noncancer pain, cancer-related pain, or spasticity.
  3. [3]
    Intrathecal pumps - PMC - PubMed Central - NIH
    Starting from Bier's 'cocainization of the spinal cord' in 1898, direct nervous system pharmacy delivery has long been recognized as an effective means to treat ...
  4. [4]
    Intrathecal Drug Delivery: Advances and Applications in the ...
    Jun 16, 2022 · IDD allows for direct administration of spinally administered agents to their location of action within the CNS. IT drug delivery in principle ...
  5. [5]
    Intrathecal Antibacterial and Antifungal Therapies - PubMed Central
    Intrathecal administration of anti-infectives is indicated in central nervous system infections by multiresistant pathogens when drugs that can reach adequate ...
  6. [6]
    Bypassing the Blood–Brain Barrier: Direct Intracranial Drug Delivery ...
    Injections or infusions of drugs into the CSF via icv or intrathecal delivery in order to bypass the BBB is clinically established and has been used for several ...
  7. [7]
    Current perspectives on intrathecal drug delivery - PMC
    History of intrathecal analgesia and intrathecal ... Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin.
  8. [8]
    Intrathecal Drug Delivery (ITDD) systems for cancer pain - PMC - NIH
    Mar 28, 2013 · In intrathecal drug delivery or ITDD, medication is delivered directly into the CSF in the intrathecal space ( Figure 1); therefore, a ...
  9. [9]
    [PDF] Methotrexate Injection, USP - accessdata.fda.gov
    Do not use the preserved formulation of Methotrexate for intrathecal or high-dose therapy because it contains benzyl alcohol. Use the preservative-free ...
  10. [10]
    Intrathecal Methotrexate Containing the Preservative Benzyl Alcohol ...
    Preserved drugs administered in error can result in significant neurotoxicity. A case series is described where preservative-containing methotrexate was ...
  11. [11]
    Intrathecal Immunoselective Nanopheresis for Alzheimer's Disease
    Oct 2, 2024 · In intrathecal pseudodelivery devices, the drug is encapsulated in a porous capsule in communication with the CSF. Here, the drug is not ...
  12. [12]
    Intrathecal antibody distribution in the rat brain: surface diffusion ...
    Oct 12, 2017 · Perivascular transport involved blood vessels of all caliber and putative smooth muscle and astroglial basement membrane compartments.
  13. [13]
    Spinal Anesthesia - NYSORA
    ... onset and duration of anesthesia, and side effects of the drug. Two distinct ... Tetracaine has an onset of anesthesia within 3 to 5 minutes and a duration ...
  14. [14]
    Spinal Opioids in Anesthetic Practice - StatPearls - NCBI Bookshelf
    Apr 2, 2023 · [6] Their onset of action, 5 to 20 minutes, is more rapid than morphine due to their hydrophobic nature. The duration of action is 1 to 4 ...Missing: reservoir | Show results with:reservoir
  15. [15]
    Pharmacokinetics and pharmacodynamics of intrathecally ...
    Xen2174 is a synthetic 13-amino acid peptide that binds specifically to the norepinephrine transporter, which results in inhibition of norepinephrine uptake.
  16. [16]
    Intrathecal morphine for postoperative analgesia: Current trends
    Cephalad spread may occur as early as 30 min when drug is detectable in cisternal CSF[5]. There is poor circumferential CSF spread around the cord from the ...
  17. [17]
    Intrathecal drug spread | BJA: British Journal of Anaesthesia
    Total CSF volume in an average adult is about 150 ml, approximately half of which is intracranial. The remainder lies within the spinal subarachnoid space and ...
  18. [18]
    Cerebrospinal Fluid Pressure - an overview | ScienceDirect Topics
    In an adult, the total volume of CSF ranges from 150 to 270 mL—25% within the ventricles and 75% within the intracranial and spinal subarachnoid space. ... In a ...
  19. [19]
    Anatomy, Back, Spinal Meninges - StatPearls - NCBI Bookshelf - NIH
    The spinal subarachnoid space is located between the arachnoid and pia mater and is filled with CSF. Arachnoid trabeculae extend between these two layers within ...
  20. [20]
    Lab 2 (ƒ4) - External and Internal Anatomy of the Spinal Cord
    It is separated from the dura by the subdural space which is more potential than real. The subarachnoid space is wider and contains cerebrospinal fluid.
  21. [21]
    Anatomy, Back, Cauda Equina - StatPearls - NCBI Bookshelf
    The cauda equina contains a bundle of nerves which project distally within the enclosed cavity of the lumbar cistern from the spinal cord and conus medullaris ...
  22. [22]
    Neuroanatomy, Spinal Cord Morphology - StatPearls - NCBI Bookshelf
    The spinal nerves L2 to S1 comprise the cauda equina within the subarachnoid space called the lumbar cistern. The spinal cord has two significant ...
  23. [23]
    Tethered Cord Syndrome (TCS) - StatPearls - NCBI Bookshelf - NIH
    Jul 31, 2023 · Tethered cord syndrome (TCS) is a stretch-induced clinical constellation arising from tension on the spinal cord due to anchoring to inelastic structures.Missing: stenosis | Show results with:stenosis
  24. [24]
    Difficult Lumbar Puncture: Pitfalls and Tips from the Trenches - PMC
    Dry taps can occur in severe spinal stenosis, including thecal sac narrowing from epidural lipomatosis (Fig 5) or arachnoiditis (Fig 3). If a fluoroscopically ...
  25. [25]
    Neuroanatomy, Cerebrospinal Fluid - StatPearls - NCBI Bookshelf
    Jul 7, 2025 · Normal CSF is clear, with pressure ranging from 8 to 15 mm Hg. Glucose concentrations typically range from 50 to 80 mg/dL or measure ...Introduction · Structure and Function · Embryology · Surgical Considerations
  26. [26]
    Physiology, Cerebral Spinal Fluid - StatPearls - NCBI Bookshelf
    Aug 9, 2025 · ... CSF renewal 4 to 5 times every 24 hours in young adults. Decreased turnover may promote metabolite accumulation observed in aging and ...
  27. [27]
    The Effect of Body Posture on Brain Glymphatic Transport
    Aug 5, 2015 · Therefore, not only the level of consciousness, but also body posture, might affect CSF–interstitial fluid (ISF) exchange efficiency. We used ...
  28. [28]
    Cerebrospinal Fluid Analysis - Medscape Reference
    Aug 21, 2025 · The total CSF volume is about 150 mL (this volume is maintained constant), but it is continuously resorbed and is produced at a rate of about ...Missing: administration | Show results with:administration
  29. [29]
    How To Do Lumbar Puncture - Neurologic Disorders - Merck Manuals
    Step-by-Step Description of Lumbar Puncture · Identify and prepare the site · Insert the spinal needle · Lumbar Puncture · Measure CSF pressure · Collect CSF.Missing: single- dose
  30. [30]
    [PDF] STANDARDIZED PROCEDURE INTRATHECAL ADMINISTRATION ...
    The administration of neurotherapeutics via lumbar puncture into cerebrospinal fluid (CSF) for treatment of previously diagnosed nervous system disease. The ...
  31. [31]
    [PDF] Intrathecal Drug Delivery - International Neuromodulation Society
    Intrathecal drug delivery systems are implanted pumps that target pain relief or anti-spasm medication to an area of the spine.
  32. [32]
    SynchroMed™ II Intrathecal Pump - Medtronic
    The SynchroMed™ II implantable infusion system delivers drug directly into the intrathecal space, thereby bypassing the blood-brain barrier.Synchromedtm Ii Intrathecal... · Features · Synchromedtm Ii Pump
  33. [33]
    Role of Catheter's Position for Final Results in Intrathecal Drug ... - NIH
    Baclofen despite his hydrophilicity, present a limited spread within the CSF showing a lumbar-to-cisternal gradient of 4:1, moreover, factors as baricity of ...
  34. [34]
    Effective Dose Range of Intrathecal Isobaric Bupivacaine to Achieve ...
    Mar 1, 2023 · The recommended doses to reach the spinal block height at T4 and T10 in adults are 12–20 and 10–15 mg, respectively [1]. As it involves ...
  35. [35]
    Ropivacaine: Is it a good choice for spinal anesthesia? - PMC - NIH
    It is less potent than bupivacaine when used in low doses such as for epidural analgesia or spinal anesthesia.
  36. [36]
    Single-dose intrathecal analgesia to control labour pain - NIH
    We use the classic lumbar puncture technique, generally with patients seated and bent forward, using a 25-gauge cone-tipped needle. Once the dura has been ...
  37. [37]
    PROSPECT guideline for elective caesarean section
    For patients undergoing elective caesarean section performed under neuraxial anaesthesia, recommendations include intrathecal morphine 50–100 µg or diamorphine ...
  38. [38]
    Intrathecal Morphine - StatPearls - NCBI Bookshelf - NIH
    The recommended starting dose of intrathecal morphine continuous infusion is 0.1 to 1.0 mg per day in patients without tolerance to opioids and variable dosing ...Continuing Education Activity · Indications · Adverse Effects · Monitoring
  39. [39]
    Intrathecal Pain Pump Infusions for Intractable Cancer Pain - NIH
    Apr 4, 2013 · We created an algorithm that predicts, for cancer patients, an appropriate initial dose for an intrathecal pump based on the prepump systemic opioid dose, thus ...
  40. [40]
    A comparative study of intrathecal clonidine and dexmedetomidine ...
    Supplementation of bupivacaine spinal block with a low dose of intrathecal dexmedetomidine (5 μg) or clonidine (50 μg) produces a significantly shorter onset of ...
  41. [41]
    Optimal Dose of Intrathecal Dexmedetomidine in Lower Abdominal ...
    Apr 1, 2016 · Weighing the prolongation of anesthesia and analgesia and side effects we conclude that 10 mcg of dexmedetomidine is optimum intrathecal dose.
  42. [42]
    Intrathecal Ziconotide: Dosing and Administration Strategies in ...
    Feb 9, 2016 · Expert consensus on IT continuous infusion with ziconotide suggests a starting dose of 0.5 to 1.2 mcg/day followed by dose titration of ≤0.5 mcg ...
  43. [43]
    Ziconotide - StatPearls - NCBI Bookshelf
    Jan 19, 2025 · Ziconotide is an intrathecal analgesic approved by the FDA for chronic severe pain in patients who are intolerant or refractory to systemic analgesics or ...
  44. [44]
    Intrathecal coadministration of bupivacaine diminishes morphine ...
    The combination of intrathecal morphine and bupivacaine resulted in a diminished progression of the intrathecal morphine dose.
  45. [45]
    Refractory Cancer Pain and Intrathecal Therapy: Critical Review of a ...
    Forty-three patients with cancer were treated by continuous intrathecal opioid therapy due to “the failure of conventional pain therapy or because of ...
  46. [46]
    Intrathecal ziconotide in the treatment of refractory pain in patients ...
    Pain relief was moderate to complete in 52.9% of patients in the ziconotide group compared with 17.5% in the placebo group (P<.001). Five patients receiving ...Missing: reduction | Show results with:reduction
  47. [47]
    Table 1_Upgrading intrathecal morphine for postoperative pain ...
    BackgroundFor major abdominal surgery, we explored “usual” opioid-avoiding effects of spinal magnesium 25 mg added to intrathecal morphine (250+ µg in women, ...
  48. [48]
    2017 Infectious Diseases Society of America's Clinical Practice ...
    Feb 14, 2017 · Dosages and intervals of intraventricular antimicrobial therapy should be adjusted based on CSF antimicrobial concentrations to 10–20 times the ...EXECUTIVE SUMMARY · INTRODUCTION · RECOMMENDATIONS AND...
  49. [49]
    Intrathecal Amphotericin B: A 60-Year Experience in Treating ...
    This article describes the practice experience in the treatment of CM, preparation of IT AmBd, and the different dosing strategies used in regard to route of ...Abstract · Intrathecal Amphotericin... · IT Amphotericin Dosing...
  50. [50]
    Intrathecal/Intraventricular Colistin for Antibiotic-Resistant Bacterial ...
    Mar 3, 2022 · Inadequate CNS penetration and intravenous (IV) antibiotic treatment failure represent a major clinical challenge. However, patients with ...
  51. [51]
    Intraventricular or intrathecal polymyxin B for treatment of post ...
    Mar 5, 2024 · Intravenous combined with IVT/ITH polymyxin B increased CSF microbiological eradication and improved clinical outcomes.
  52. [52]
    Acute Lymphoblastic Leukemia Treatment (PDQ®) - NCBI - NIH
    Apr 14, 2025 · Intrathecal chemotherapy may be used to treat ALL that has spread, or may spread, to the brain and spinal cord. Intrathecal chemotherapy is ...
  53. [53]
    Intrathecal liposomal cytarabine plus systemic therapy versus ...
    A randomized open-label phase III study to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metastasis (LM).
  54. [54]
    How we treat patients with leptomeningeal metastases - PMC
    May 21, 2019 · Recently, improvement of leptomeningeal disease–related progression-free survival by adding intrathecal liposomal cytarabine to systemic ...
  55. [55]
    Central Nervous System Prophylaxis and Treatment in Acute ...
    Dec 13, 2022 · Different intrathecal prophylaxis regimens have been explored in ALL, including triple intrathecal therapy (methotrexate, cytarabine, prednisone) ...
  56. [56]
    Intrathecal liposomal cytarabine: More friend than foe? - PMC
    Intrathecal chemotherapy is an integral component of treatment for acute leukemia and non-Hodgkin lymphoma, and together with intensive systemic ...
  57. [57]
    Liposomal cytarabine in the prophylaxis and treatment of CNS ...
    The CNS half-life of an intrathecal liposomal cytarabine in a 12.5–75 mg dose is 29- to 77-fold greater than a 30 mg dose of intrathecal free cytarabine (100– ...
  58. [58]
    [PDF] 21-041 DepoCyt Medical Review - accessdata.fda.gov
    Oct 2, 1998 · 1.1.6 Dosage Form and route of administration: Five ml (10 mg/ml) ready to use vials for intrathecal injection.
  59. [59]
    Intrathecal thiotepa: reappraisal of an established therapy - PubMed
    ... intrathecal thiotepa at 5 to 11.5 mg/m2 per dose for two to seven doses. Five children received concomitant craniospinal irradiation; 12 received ...
  60. [60]
    A review on intrathecal administration of medications for ...
    This article presents a comprehensive review of the current advancements in IT administration of chemotherapy, targeted, and immunotherapy drugs for the ...<|control11|><|separator|>
  61. [61]
    Ommaya Reservoir - StatPearls - NCBI Bookshelf
    Aug 24, 2025 · This device provides direct access to the cerebrospinal fluid (CSF), enabling repeated intraventricular drug administration—such as chemotherapy ...Continuing Education Activity · Introduction · Indications · Technique or Treatment
  62. [62]
    Ommaya Reservoir Use in Pediatric ALL and NHL: A Review at St ...
    Feb 28, 2024 · The intraventricular route of chemotherapy administration, via an Ommaya Reservoir (OmR) improves drug distribution in the central nervous ...
  63. [63]
    Vincristine - StatPearls - NCBI Bookshelf - NIH
    Oct 30, 2023 · The administration of vincristine via intrathecal routes typically leads to fatal outcomes. Therefore, all syringes containing vincristine must ...
  64. [64]
    Death and Neurological Devastation From Intrathecal Vinca Alkaloids
    The first reported case of fatal ascending myeloencephalopathy caused by the intrathecal administration of IV vinCRIStine occurred in the US in 1968.
  65. [65]
    Intrathecal delivery of nanoparticle PARP inhibitor to the ...
    These degradable polymer nanoparticles improve the therapeutic index when delivered intrathecally and lead to sustained drug retention in the tumor as measured ...
  66. [66]
    RePORT RePORTER - National Institutes of Health (NIH) |
    Here, we will develop new approaches to treat LM through intrathecal delivery of chemotherapeutic, radiation sensitizing nanoparticles. NIH Spending ...
  67. [67]
    Intrathecal baclofen pump for spasticity: an evidence-based analysis
    May 1, 2005 · Level 2 evidence supports the effectiveness of intrathecal baclofen infusion for the short-term reduction of severe spasticity in patients ...
  68. [68]
    Intrathecal baclofen efficacy for managing motor function and ...
    Apr 27, 2024 · The purpose of this study is to investigate the impact of intrathecal baclofen (ITB) therapy on severe40.23 spasticity and motor function in patients with ...
  69. [69]
    Treatment of spasticity with intrathecal Baclofen administration
    Aug 10, 2004 · The average effective test dose of baclofen was 100.5±84.34 μg for spinal diseases and 143.5±197.32 μg for spasticity of cerebral origin. Test ...
  70. [70]
    Efficacy - HCP - Lioresal® Intrathecal
    ITB Therapy with Lioresal Intrathecal (baclofen injection) has a well-established efficacy profile for severe spasticity.
  71. [71]
    SPINRAZA® (nusinersen) Dosing & Administration | HCP
    The recommended dosage is 12 mg (5 mL) per administration. Treatment with SPINRAZA begins with 4 starting, or loading, doses.Only 3 Times A Year After... · Spinraza Has One Dosing... · What Are The Guidelines For...
  72. [72]
    Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular ...
    Nov 2, 2017 · Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function ...Nusinersen Versus Sham... · Trial Procedures And... · Efficacy<|control11|><|separator|>
  73. [73]
    FDA approves treatment of ALS associated with a mutation in the ...
    Apr 25, 2023 · FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene ...
  74. [74]
    Tofersen | The ALS Association
    Tofersen was shown to reduce levels of the SOD1 protein in cerebral spinal fluid by 35% as early as eight weeks after participants began receiving the therapy.
  75. [75]
    Best Practices for Intrathecal Baclofen Therapy: Screening Test
    The standard baclofen test dose is a 50-mcg bolus, 25 mcg in very small children or patients who rely on spasticity for mobility. Patients unresponsive to ...
  76. [76]
    Intrathecal delivery of adipose-derived mesenchymal stem cells in ...
    Apr 1, 2024 · Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal cord ...
  77. [77]
    Assessment of mesenchymal stem cells for the treatment of spinal ...
    Apr 16, 2025 · The results showed that MSCs significantly improved motor, sensory, and activities of daily living activities after SCI. Network meta-analysis ...
  78. [78]
    Roche provides an update on tominersen: What's next for ... - HDBuzz
    Apr 17, 2025 · Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, ...Missing: intrathecal 2023-2025
  79. [79]
    Extracellular Vesicles Administered via Intrathecal Injection Mediate ...
    Jul 7, 2025 · Extracellular vesicles administered via intrathecal injection mediate safe delivery of nucleic acids to the central nervous system for gene therapy.
  80. [80]
    Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood ...
    This review assesses intrathecal (IT) nanoparticle (NP) delivery systems that aim to enhance drug delivery by circumventing the BCSFB.
  81. [81]
    Intrathecal Therapies for Neurodegenerative Diseases: A Review of ...
    Sep 5, 2025 · The intrathecal (IT) route of drug administration involves delivering therapeutic agents directly into the CSF, bypassing the restrictive blood– ...<|control11|><|separator|>
  82. [82]
    Intrathecal Therapy 2025 to Grow at 5 CAGR with 2446.6 million ...
    Jul 5, 2025 · The global intrathecal therapy market is projected to reach \$2446.6 million in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 5% from ...Missing: intracisternal cervical
  83. [83]
    Ongoing challenges of off-label prescribing - PMC - NIH
    Dec 12, 2023 · Prescribers need to be aware of the safety, ethical and financial considerations associated with off-label prescribing. They should use ...Missing: intrathecal phase II 2023-2025
  84. [84]
    Absorbable Antibacterial Envelope Reduces Surgical Site Infections ...
    May 15, 2025 · Intrathecal drug-delivery system implantation infection rates traditionally range from approximately 2.5–9%. Potential SSI with intrathecal drug ...
  85. [85]
    Adverse Events and Complications Associated With Intrathecal Drug ...
    The top three reasons for adverse report are infection/erosion (15.7%, n = 157), motor stall (12.4%, n = 125) and adverse medication reactions (11.8%, n = 119), ...
  86. [86]
    [Spinal catheter-associated cerebrospinal fluid leak] - PubMed
    Cerebrospinal fluid leak, with its typical postdural puncture headache, occurs in 8-25 % of patients after insertion of a spinal catheter.
  87. [87]
    Rate of complications among the recipients of intrathecal baclofen ...
    Device-related and surgical wound infection occurred in 12 patients (3%), and nine were regarded as severe. Leakage or subcutaneous accumulation of the ...<|control11|><|separator|>
  88. [88]
    Intrathecal catheter-tip inflammatory masses: an intraparenchymal ...
    Extramedullary intrathecal granuloma formation is a rare complication of morphine administration via implanted drug delivery systems. More than 95,000 drug ...Missing: occlusion | Show results with:occlusion
  89. [89]
    Device-related complications of long-term intrathecal drug therapy ...
    Mar 11, 2008 · The annual rate for complications requiring surgical measures was 10.5%, with 35% being pump related and 65% being catheter related.<|control11|><|separator|>
  90. [90]
    Infectious complications related to intrathecal drug delivery system ...
    Four infectious complications were noted with an overall infectious risk of 2.8%. The infection rate was 2.4% for IDD systems versus 3.4% for SCS systems (P = 1) ...
  91. [91]
    [PDF] Corning and cocaine: the advent of spinal anaesthesia
    Spinal anaesthesia was first identified inadvertently by Leonard Corning in New York in 1885. Subsequently, August Bier employed the technique successfully ...
  92. [92]
    Spinal Anesthesia - StatPearls - NCBI Bookshelf
    The first regional anesthetic technique performed was spinal anesthesia, and the first operation under spinal anesthesia was in 1898 in Germany by August Bier.
  93. [93]
    A history of neuraxial administration of local analgesics and opioids
    Jul 11, 2005 · Shortly afterwards, in 1901, Katawata [38] of Japan reported the injection of morphine 10 mg and a local anaesthetic into the intrathecal space ...Missing: intraspinal | Show results with:intraspinal
  94. [94]
    History and present state of targeted intrathecal drug delivery
    Nearly 50 years ago, the seminal experiments of Melzack and Wall, culminating in the gate control theory, coupled with the discovery of endogenous opioid ...
  95. [95]
    Brief History of Neuromodulation
    Aug 31, 2022 · Intrathecal morphine was first used for cancer pain but is now used for severe pain of non-cancer origin in patients with normal life expectancy ...
  96. [96]
    Drug Approval Package: DepoCyt (Cytarabine Liposomal) NDA# 21 ...
    Jul 5, 2002 · DepoCyt (Cytarabine Liposomal) Injection. Company: DepoTech Corporation. Application No.: 21-041. Approval Date: 8/1/1999. Date created: July 05, 2002.
  97. [97]
    U.S. FDA Approves Biogen's SPINRAZA™ (nusinersen), The First ...
    Dec 23, 2016 · SPINRAZA™ (nusinersen) was approved by the U.S. FDA in December 2016 for the treatment of spinal muscular atrophy (SMA) in pediatric and adult ...
  98. [98]
    The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica ...
    Patients in this group will receive extracellular vesicles derived from human-induced neural stem cells for intrathecal injection once a day for 1 day.
  99. [99]
    Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous ...
    May 3, 2025 · This research explores lipid nanoparticles (LNPs) for enhancing mRNA delivery to the central nervous system via intrathecal injection.
  100. [100]
    High Cervical Intrathecal Targeted Drug Delivery for Refractory ...
    Jun 28, 2025 · High cervical intrathecal drug delivery can be an effective treatment option for patients with refractory neuropathic craniofacial pain.Missing: studies | Show results with:studies